TLDR
- Realty Income yields above 5% and has raised its dividend over 120 times since listing
- Verizon has grown its dividend annually for nearly two decades and is a top high-yield blue-chip
- Pfizer’s yield has risen as its share price pulled back following the drop in COVID revenue
Three dividend stocks are standing out for income investors in 2026. Each one offers a different approach to generating reliable returns.
Realty Income: Monthly Payouts and a 5% Yield
Realty Income has built its entire identity around income. The company owns thousands of commercial properties leased to major tenants under long-term contracts.
It has raised its dividend more than 120 times since going public and currently yields above 5%. Its portfolio covers retail, industrial, and gaming properties, spreading risk across multiple sectors.
The stock pays monthly, which sets it apart from most dividend stocks that pay quarterly. For investors who want regular income, that cadence is a draw.
Analyst consensus sits at 7 Buy, 7 Hold, and 1 Sell, with an average price target of around $67.35.
Verizon: Steady Income From a Telecom Giant
Verizon has raised its dividend every year for close to two decades. The company’s wireless and broadband services generate steady cash flow, and its customer base is large.
Verizon Communications Inc., VZ
Growth has been slow, but the services it provides are essential. That makes the revenue stream relatively predictable compared to more cyclical businesses.
The stock remains one of the highest-yielding large-cap names in the U.S. market. Investors tend to choose it for income and lower price swings rather than capital gains.
For investors who want a defensive income stock with a long track record, Verizon fits that role.
Pfizer: A High Yield With a Recovery Angle
Pfizer’s share price pulled back after COVID vaccine revenue declined sharply. That drop pushed the dividend yield higher, which has attracted income-focused investors.
The company still has a broad drug pipeline and continues investing in research and development. Newer products in its portfolio are being watched to see if they can replace the revenue lost from pandemic-related sales.
Pfizer still carries a wide analyst following and has not cut its dividend despite the revenue slowdown. That has kept it on the watchlist for investors willing to take on some uncertainty.
Investors with patience may benefit if the newer drugs gain traction over the next few years.
4th of July Flash Sale – 50% OFF!
Celebrate Independence Day by investing in your future. For a limited time, get 50% OFF a Knockout Stocks membership and unlock our latest high-conviction stock picks, powered by our proprietary KO Score algorithm.
You'll also get access to our long-term investment ideas and shorter-term trade opportunities, helping you identify potential opportunities before the crowd.
Sign up to Knockout Stocks today and get 50% OFF to unlock the full list of premium stock picks.
Use coupon code SPECIAL50 for your exclusive discount.
Offer ends soon. Don't miss out!
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
